Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | FABP2 | P12104 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11754794 | 0.87 | NPC1 (0.69) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10294117 | 0.87 | EPHX2 (0.50) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22693604 | 0.86 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1FABP2 | |
| SCHEMBL13753142 | 0.86 | HDAC3 (0.66) | PPARGPPARDPPARAHDAC3HDAC1 | |
| SCHEMBL13918749 | 0.82 | KDM4E (0.70) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10294705 | 0.82 | L3MBTL1 (0.60) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6360344 | 0.81 | NPC1 (0.75) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10294667 | 0.80 | NPC1 (0.81) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17302418 | 0.80 | NPC1 (0.63) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14615882 | 0.80 | RAB9A (0.68) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | NPC1 87/4885RAB9A 3470/4885KMT2A 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.